QuidelOrtho Corporation (QDEL)
NASDAQ: QDEL · Real-Time Price · USD
35.51
-1.91 (-5.10%)
May 13, 2025, 4:00 PM - Market closed
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2014 - 2019 |
| Labs | 1.43B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Labs Growth | 0.09% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Point of Care | 694.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Point of Care Growth | -22.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Molecular Diagnostics | 24.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Molecular Diagnostics Growth | -24.29% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Immunohematology | 522.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Immunohematology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Donor Screening | 115.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Donor Screening Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Transfusion Medicine | 638.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Transfusion Medicine Growth | -1.60% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2014 - 2019 |
| North America Adjusted EBITDA | 892.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America Adjusted EBITDA Growth | -6.02% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Adjusted EBITDA | 46.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Adjusted EBITDA Growth | -20.24% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Adjusted EBITDA | 130.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Adjusted EBITDA Growth | 1.08% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies Adjusted EBITDA | 133.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies Adjusted EBITDA Growth | 14.79% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Adjusted EBITDA | -659.70M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Adjusted EBITDA Growth | 24.54% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2014 - 2019 |
| North America | 1.62B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America Growth | -13.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA | 335.80M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Growth | 2.60% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China | 325.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | 4.80% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies | 502.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies Growth | 3.93% |
Log In |
Log In |
Log In |
Log In | Upgrade
|